Suramin inhibits the CD40-CD154 costimulatory interaction

A possible mechanism for immunosuppressive effects

Emilio Margolles-Clark, M. Caroline Jacques-Silva, Lakshmi Ganesan, Oliver Umland, Norma S Kenyon, Camillo Ricordi, Per Olof Berggren, Peter Buchwald

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Suramin is a symmetric polysulfonated naphthylamine-benzamide urea derivative approved for the treatment of trypanosomiasis and onchocerciasis and a known P2 (ATP/UTP purine receptor) antagonist. Here, we report its ability to inhibit the important CD40-CD154 costimulatory interaction required for T cell activation and the development of an effective immune response. In vitro, it inhibited the binding of both human and murine CD154 (CD40L) to their receptor (CD40) even in the presence of protein-containing media and prevented the CD154-induced proliferation of human B cells as well as the corresponding increase in surface expression of CD86, CD80, CD40, and MHC class II in a concentration-dependent manner. Furthermore, in isolated human islets, it also decreased the CD154-induced release of inflammatory cytokines such as IFN-γ, interleukin-6 (IL-6), and IL-8. Suramin was selected for investigation because it has been reported to be an inhibitor of the interaction of TNF-α with its receptor and CD154 is a member of the TNF-family. However, it turned out to be a considerably, about 30-fold, more effective inhibitor of the CD40-CD154 protein-protein interaction than of the corresponding TNF interaction. Its median inhibitory concentration (IC50 ≈ 50 μM) is somewhat higher than for the P2-receptor, but well within the range of its therapeutic concentration levels. Suramin shows considerable polypharmacology, but its interference with the positive costimulatory interaction might provide a possible, not yet identified mechanism for its ability to suppress T cell activity and induce immunosuppression, which might also have limited its clinical usefulness in the treatment of AIDS and cancer.

Original languageEnglish
Pages (from-to)1236-1245
Number of pages10
JournalBiochemical Pharmacology
Volume77
Issue number7
DOIs
StatePublished - Apr 1 2009

Fingerprint

Suramin
Immunosuppressive Agents
Aptitude
T-cells
Inhibitory Concentration 50
Polypharmacology
Onchocerciasis
T-Lymphocytes
Purinergic Receptors
CD40 Ligand
Uridine Triphosphate
Proteins
Trypanosomiasis
Interleukin-8
Immunosuppression
Urea
Interleukin-6
Acquired Immunodeficiency Syndrome
B-Lymphocytes
Therapeutics

Keywords

  • CD40 ligand
  • Costimulation
  • Immunosuppression
  • Protein-protein interaction
  • Suramin

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Suramin inhibits the CD40-CD154 costimulatory interaction : A possible mechanism for immunosuppressive effects. / Margolles-Clark, Emilio; Jacques-Silva, M. Caroline; Ganesan, Lakshmi; Umland, Oliver; Kenyon, Norma S; Ricordi, Camillo; Berggren, Per Olof; Buchwald, Peter.

In: Biochemical Pharmacology, Vol. 77, No. 7, 01.04.2009, p. 1236-1245.

Research output: Contribution to journalArticle

Margolles-Clark, Emilio ; Jacques-Silva, M. Caroline ; Ganesan, Lakshmi ; Umland, Oliver ; Kenyon, Norma S ; Ricordi, Camillo ; Berggren, Per Olof ; Buchwald, Peter. / Suramin inhibits the CD40-CD154 costimulatory interaction : A possible mechanism for immunosuppressive effects. In: Biochemical Pharmacology. 2009 ; Vol. 77, No. 7. pp. 1236-1245.
@article{756b075564724f6b9086e79ec7202d82,
title = "Suramin inhibits the CD40-CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects",
abstract = "Suramin is a symmetric polysulfonated naphthylamine-benzamide urea derivative approved for the treatment of trypanosomiasis and onchocerciasis and a known P2 (ATP/UTP purine receptor) antagonist. Here, we report its ability to inhibit the important CD40-CD154 costimulatory interaction required for T cell activation and the development of an effective immune response. In vitro, it inhibited the binding of both human and murine CD154 (CD40L) to their receptor (CD40) even in the presence of protein-containing media and prevented the CD154-induced proliferation of human B cells as well as the corresponding increase in surface expression of CD86, CD80, CD40, and MHC class II in a concentration-dependent manner. Furthermore, in isolated human islets, it also decreased the CD154-induced release of inflammatory cytokines such as IFN-γ, interleukin-6 (IL-6), and IL-8. Suramin was selected for investigation because it has been reported to be an inhibitor of the interaction of TNF-α with its receptor and CD154 is a member of the TNF-family. However, it turned out to be a considerably, about 30-fold, more effective inhibitor of the CD40-CD154 protein-protein interaction than of the corresponding TNF interaction. Its median inhibitory concentration (IC50 ≈ 50 μM) is somewhat higher than for the P2-receptor, but well within the range of its therapeutic concentration levels. Suramin shows considerable polypharmacology, but its interference with the positive costimulatory interaction might provide a possible, not yet identified mechanism for its ability to suppress T cell activity and induce immunosuppression, which might also have limited its clinical usefulness in the treatment of AIDS and cancer.",
keywords = "CD40 ligand, Costimulation, Immunosuppression, Protein-protein interaction, Suramin",
author = "Emilio Margolles-Clark and Jacques-Silva, {M. Caroline} and Lakshmi Ganesan and Oliver Umland and Kenyon, {Norma S} and Camillo Ricordi and Berggren, {Per Olof} and Peter Buchwald",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.bcp.2009.01.001",
language = "English",
volume = "77",
pages = "1236--1245",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Suramin inhibits the CD40-CD154 costimulatory interaction

T2 - A possible mechanism for immunosuppressive effects

AU - Margolles-Clark, Emilio

AU - Jacques-Silva, M. Caroline

AU - Ganesan, Lakshmi

AU - Umland, Oliver

AU - Kenyon, Norma S

AU - Ricordi, Camillo

AU - Berggren, Per Olof

AU - Buchwald, Peter

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Suramin is a symmetric polysulfonated naphthylamine-benzamide urea derivative approved for the treatment of trypanosomiasis and onchocerciasis and a known P2 (ATP/UTP purine receptor) antagonist. Here, we report its ability to inhibit the important CD40-CD154 costimulatory interaction required for T cell activation and the development of an effective immune response. In vitro, it inhibited the binding of both human and murine CD154 (CD40L) to their receptor (CD40) even in the presence of protein-containing media and prevented the CD154-induced proliferation of human B cells as well as the corresponding increase in surface expression of CD86, CD80, CD40, and MHC class II in a concentration-dependent manner. Furthermore, in isolated human islets, it also decreased the CD154-induced release of inflammatory cytokines such as IFN-γ, interleukin-6 (IL-6), and IL-8. Suramin was selected for investigation because it has been reported to be an inhibitor of the interaction of TNF-α with its receptor and CD154 is a member of the TNF-family. However, it turned out to be a considerably, about 30-fold, more effective inhibitor of the CD40-CD154 protein-protein interaction than of the corresponding TNF interaction. Its median inhibitory concentration (IC50 ≈ 50 μM) is somewhat higher than for the P2-receptor, but well within the range of its therapeutic concentration levels. Suramin shows considerable polypharmacology, but its interference with the positive costimulatory interaction might provide a possible, not yet identified mechanism for its ability to suppress T cell activity and induce immunosuppression, which might also have limited its clinical usefulness in the treatment of AIDS and cancer.

AB - Suramin is a symmetric polysulfonated naphthylamine-benzamide urea derivative approved for the treatment of trypanosomiasis and onchocerciasis and a known P2 (ATP/UTP purine receptor) antagonist. Here, we report its ability to inhibit the important CD40-CD154 costimulatory interaction required for T cell activation and the development of an effective immune response. In vitro, it inhibited the binding of both human and murine CD154 (CD40L) to their receptor (CD40) even in the presence of protein-containing media and prevented the CD154-induced proliferation of human B cells as well as the corresponding increase in surface expression of CD86, CD80, CD40, and MHC class II in a concentration-dependent manner. Furthermore, in isolated human islets, it also decreased the CD154-induced release of inflammatory cytokines such as IFN-γ, interleukin-6 (IL-6), and IL-8. Suramin was selected for investigation because it has been reported to be an inhibitor of the interaction of TNF-α with its receptor and CD154 is a member of the TNF-family. However, it turned out to be a considerably, about 30-fold, more effective inhibitor of the CD40-CD154 protein-protein interaction than of the corresponding TNF interaction. Its median inhibitory concentration (IC50 ≈ 50 μM) is somewhat higher than for the P2-receptor, but well within the range of its therapeutic concentration levels. Suramin shows considerable polypharmacology, but its interference with the positive costimulatory interaction might provide a possible, not yet identified mechanism for its ability to suppress T cell activity and induce immunosuppression, which might also have limited its clinical usefulness in the treatment of AIDS and cancer.

KW - CD40 ligand

KW - Costimulation

KW - Immunosuppression

KW - Protein-protein interaction

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=61449238962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449238962&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.01.001

DO - 10.1016/j.bcp.2009.01.001

M3 - Article

VL - 77

SP - 1236

EP - 1245

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -